The Role of Optical Coherence Tomography in Differential Diagnosis of Multiple Sclerosis and Autoimmune Connective Tissue Diseases with CNS Involvement

• Published in: Journal of clinical medicine Vol. 9; no. 5; p. 1565
• Main Authors: Wildner, Paula, Zydorczak, Ewa, Oset, Magdalena, Siger, Małgorzata, Wilczyński, Michał, Stasiołek, Mariusz, Matysiak, Mariola
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21-05-2020; MDPI
• Subjects: Arthritis; Clinical medicine; Connective tissue diseases; Lupus; Magnetic resonance imaging; Multiple sclerosis; Optics; Patients; Software; Tomography; Poland; differential diagnosis; rheumatic disorders; autoimmune connective tissue diseases; optical coherence tomography; multiple sclerosis
• DOI: 10.3390/jcm9051565
• EISSN: 2077-0383

The purpose of this study was to examine whether application of optical coherence tomography (OCT) measurements can provide a useful biomarker for distinguishing central nervous system (CNS) involvement in autoimmune connective tissue diseases (CTD) from multiple sclerosis (MS). An observational study included non-optic neuritis eyes of 121 individuals: 59 patients with MS, 30 patients with CNS involvement in CTD, and 32 healthy controls. OCT examination was performed in all subjects to measure retinal nerve fiber layer (RNFL) thickness, ganglion cell complex (GCC) thickness, ganglion cell layer-inner plexiform layer (GCIPL) thickness, and volume of the macula. There was a significant group effect with regard to superior optic disc RNFL, macular RNFL, GCC, and GCIPL thickness, and macular volume. Post-hoc analysis revealed that MS patients have significantly smaller macular volume and thinner superior optic disc RNFL, macular RNFL, GCC, and GCIPL compared to healthy controls. CTD patients have significantly smaller superior optic disc RNFL, GCIPL, and GCC thickness compared to healthy controls. However, no significant group differences were observed between the patient groups (MS vs. CTD) on any outcome. Although a prominent retinal thinning may be a useful biomarker in MS patients, in a general population of individuals with a confirmed CNS involvement the use of OCT is not specific enough to discriminate between MS and autoimmune CTD.